阿德福韦酯治疗乙型肝炎失代偿期肝硬化临床研究(1)
参见附件(12kb)。
【摘要】 目的 探讨阿德福韦酯治疗乙型肝炎失代偿期肝硬化的临床效果。 方法 选择本院 2008年10月至2010年 10月乙型肝炎失代偿期肝硬化患者 78例，随机分为阿德福韦酯组和恩替卡韦组。两组在采用常规治疗的基础上，阿德福韦酯组给予阿德福韦酯，恩替卡韦组给予恩替卡韦，两组患者疗程为 48 周。测定两组患者治疗后HBV-DNA 阴转率。 结果 阿德福韦酯组治疗后HBV-DNA 转阴率与恩替卡韦组比较，差异无统计学意义(P>0.05)。 结论 与恩替卡韦相比，阿德福韦酯能够快速抑制乙型肝炎失代偿期肝硬化患者病毒复制。
【关键词】 阿德福韦酯；乙型肝炎；肝硬化
Clinical observation of Adefovir Dipivoxil on liver decompensated cirrhosis of reactive type B hepatitis YE Peng， SHI Bao-sheng. Hebi Hospital of Infectious Diseases，Hebi 458000，China
【Abstract】 Objective To explore the clinical observation of Adefovir Dipivoxil on liver decompensated cirrhosis of reactive type B hepatitis. Methods 78 cases with decompensated liver cirrhosis of reactive type B hepatitis were selected from October 2007 to August 2009， and divided into adefovir group and entecavir group. Adefovir treatment was used to adefovir group， and Entecavir was given to entecavir group on the base of routine treatment, the course was 48 weeks, the rate of HBV-DNA turn to negative was detected after treatment. Results the rate of HBV-DNA turn to negativet in adefovir group compared after treatment with entecavir group, there was no statistical difference (P>0.05). Conclusion Compare with Entecavir,Adefovir Dipivoril can inhabit the copy of type Bhepatitis on liver decompensated cirrhosis.
【Key words】 Adefovir Dipivoxil; Liver cirrhosis; Type B hepatitis;
作者单位：458000 鹤壁市传染病医院
慢性乙型肝炎(CHB)失代偿期肝硬化并发症多，病死率高，病毒的活动性复制在该病的发展中扮演着重要角色。近年研究证明，对慢性乙型肝炎失代偿肝硬化患者积极开展抗病毒治疗，可促使病毒载量降低或阴转，从而阻止病情发展，维持稳定状态，甚至可完全避免原位肝移植手术 ......
【摘要】 目的 探讨阿德福韦酯治疗乙型肝炎失代偿期肝硬化的临床效果。 方法 选择本院 2008年10月至2010年 10月乙型肝炎失代偿期肝硬化患者 78例，随机分为阿德福韦酯组和恩替卡韦组。两组在采用常规治疗的基础上，阿德福韦酯组给予阿德福韦酯，恩替卡韦组给予恩替卡韦，两组患者疗程为 48 周。测定两组患者治疗后HBV-DNA 阴转率。 结果 阿德福韦酯组治疗后HBV-DNA 转阴率与恩替卡韦组比较，差异无统计学意义(P>0.05)。 结论 与恩替卡韦相比，阿德福韦酯能够快速抑制乙型肝炎失代偿期肝硬化患者病毒复制。
【关键词】 阿德福韦酯；乙型肝炎；肝硬化
Clinical observation of Adefovir Dipivoxil on liver decompensated cirrhosis of reactive type B hepatitis YE Peng， SHI Bao-sheng. Hebi Hospital of Infectious Diseases，Hebi 458000，China
【Abstract】 Objective To explore the clinical observation of Adefovir Dipivoxil on liver decompensated cirrhosis of reactive type B hepatitis. Methods 78 cases with decompensated liver cirrhosis of reactive type B hepatitis were selected from October 2007 to August 2009， and divided into adefovir group and entecavir group. Adefovir treatment was used to adefovir group， and Entecavir was given to entecavir group on the base of routine treatment, the course was 48 weeks, the rate of HBV-DNA turn to negative was detected after treatment. Results the rate of HBV-DNA turn to negativet in adefovir group compared after treatment with entecavir group, there was no statistical difference (P>0.05). Conclusion Compare with Entecavir,Adefovir Dipivoril can inhabit the copy of type Bhepatitis on liver decompensated cirrhosis.
【Key words】 Adefovir Dipivoxil; Liver cirrhosis; Type B hepatitis;
作者单位：458000 鹤壁市传染病医院
慢性乙型肝炎(CHB)失代偿期肝硬化并发症多，病死率高，病毒的活动性复制在该病的发展中扮演着重要角色。近年研究证明，对慢性乙型肝炎失代偿肝硬化患者积极开展抗病毒治疗，可促使病毒载量降低或阴转，从而阻止病情发展，维持稳定状态，甚至可完全避免原位肝移植手术 ......
您现在查看是摘要介绍页，详见PDF附件(12kb)。